

**Reference:** FOI.ICB-2223/146

**Subject:** Local Treatment Guidelines Non-Small Cell Lung Cancer

*I can confirm that the CCG does not hold the information requested; please see responses below:*

QUESTION			RESPONSE
Does NHS Bristol, North Somerset and South Gloucestershire ICB have any local treatment guidelines/pathways/protocols/algorithms for the treatment of non-small cell lung cancer?	Yes	No	Bristol, North Somerset and South Gloucestershire Integrated Care Board (BNSSG ICB) does not hold this information.
	If Yes please provide a copy.		
Question 2			<p>We advise you to contact the acute hospital trusts and/or NHS England Specialised Services (<a href="https://www.england.nhs.uk/commissioning/spec-services/">https://www.england.nhs.uk/commissioning/spec-services/</a> )</p> <p>NHS England: <a href="https://www.england.nhs.uk/contact-us/foi/">https://www.england.nhs.uk/contact-us/foi/</a></p> <p>North Bristol NHS Trust (NBT): <a href="https://www.nbt.nhs.uk/about-us/information-governance/freedom-information/request-information">https://www.nbt.nhs.uk/about-us/information-governance/freedom-information/request-information</a></p> <p>University Hospitals Bristol and Weston NHS Foundation Trust (UHBW): <a href="https://www.uhbw.nhs.uk/p/how-we-use-your-data/freedom-of-information-foi-requests/">https://www.uhbw.nhs.uk/p/how-we-use-your-data/freedom-of-information-foi-requests/</a> / <a href="mailto:FreedomOfInfo@uhbw.nhs.uk">FreedomOfInfo@uhbw.nhs.uk</a></p>
Does NHS Bristol, North Somerset and South Gloucestershire ICB have protocols for the use of the following targeted drug therapies in the treatment of non-small cell lung cancer?			
Sotorasib (Lumykras)	Yes	No	
	If yes please see question 3		
Entrectinib (Rozlytrek)	Yes	No	
Larotrectinib (Vitrakvi)	Yes	No	
Dabrafenib (Tafinlar)	Yes	No	
Trametinib (Mekinist)	Yes	No	
Capmatinib (Tabrecta)	Yes	No	
Tepotinib (Tepmetko)	Yes	No	

Bevacizumab (Avastin)	Yes	No
Ramucirumab (Cyramza)	Yes	No
Atezolizumab (Tecentriq)	Yes	No
Durvalumab (Imfinzi)	Yes	No
Cemiplimab- (Libtayo)	Yes	No
Nivolumab (Opdivo)	Yes	No
Pembrolizumab (Keytruda)	Yes	No
Ipilimumab (Yervoy)	Yes	No
Afatinib (Giotrif)	Yes	No
Dacomitinib (Vizimpro)	Yes	No
Erlotinib (Tarceva)	Yes	No
Gefitinib (Iressa)	Yes	No
Osimertinib (Tagrisso)	Yes	No
Amivantamab (Rybrevant)	Yes	No
Mobocertinib (Exkivity)	Yes	No
trastuzumab deruxtecan (Enhertu)	Yes	No
Alectinib (Alecensa)	Yes	No
Brigatinib (Alunbrig)	Yes	No
Ceritinib (Zykadia)	Yes	No
Crizotinib (Xalkori)	Yes	No
Lorlatinib (Lorviqua )	Yes	No
Entrectinib (Rozlytrek)	Yes	No
Pralsetinib (Gavreto)	Yes	No
Selpercatinib (Retsevmo)	Yes	No
Nintedanib (Vargatef®)	Yes	No

Question 3

If a local protocol for the use of Sotorasib (Lumykras) for the treatment of non-small cell lung cancer is available please could a copy be provided?			
Question 4			
Does NHS Bristol, North Somerset and South Gloucestershire ICB have any local pathways/protocols/guidelines for the use of molecular biomarker testing in diagnosis/treatment of non-small cell lung cancer?	Yes	No	If yes please provide a copy
Question 5			
Is NHS Bristol, North Somerset and South Gloucestershire ICB part of a Cancer alliance or network, if so which ones?			

***The information provided in this response is accurate as of 22 December 2022 and has been approved for release by Rosi Shepherd, Chief Nursing Officer for NHS Bristol, North Somerset and South Gloucestershire CCG.***